KR101665009B1 - 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 - Google Patents

비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
KR101665009B1
KR101665009B1 KR1020120024632A KR20120024632A KR101665009B1 KR 101665009 B1 KR101665009 B1 KR 101665009B1 KR 1020120024632 A KR1020120024632 A KR 1020120024632A KR 20120024632 A KR20120024632 A KR 20120024632A KR 101665009 B1 KR101665009 B1 KR 101665009B1
Authority
KR
South Korea
Prior art keywords
group
peptide
region
pharmaceutical composition
exendin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020120024632A
Other languages
English (en)
Korean (ko)
Other versions
KR20130103190A (ko
Inventor
임세영
박성희
신령애
최인영
권세창
Original Assignee
한미사이언스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020120024632A priority Critical patent/KR101665009B1/ko
Application filed by 한미사이언스 주식회사 filed Critical 한미사이언스 주식회사
Priority to ARP130100760A priority patent/AR090287A1/es
Priority to EP13757286.3A priority patent/EP2838549B1/en
Priority to AU2013228152A priority patent/AU2013228152C1/en
Priority to US14/383,954 priority patent/US20150056223A1/en
Priority to JP2014560859A priority patent/JP2015510880A/ja
Priority to TW107146976A priority patent/TW201919688A/zh
Priority to DK13757286.3T priority patent/DK2838549T3/da
Priority to CA2864250A priority patent/CA2864250C/en
Priority to HUE13757286A priority patent/HUE057245T2/hu
Priority to CN201380013141.0A priority patent/CN104159597A/zh
Priority to SG11201404733UA priority patent/SG11201404733UA/en
Priority to MX2014010542A priority patent/MX2014010542A/es
Priority to TW102108194A priority patent/TWI658835B/zh
Priority to IN6694DEN2014 priority patent/IN2014DN06694A/en
Priority to CN201811396462.4A priority patent/CN110075277A/zh
Priority to PL13757286T priority patent/PL2838549T3/pl
Priority to HK14112891.9A priority patent/HK1199220A1/xx
Priority to RU2014133615A priority patent/RU2635966C2/ru
Priority to PCT/KR2013/001897 priority patent/WO2013133667A1/en
Priority to NZ628828A priority patent/NZ628828A/en
Priority to PT137572863T priority patent/PT2838549T/pt
Priority to MYPI2014002334A priority patent/MY167214A/en
Priority to ES13757286T priority patent/ES2900823T3/es
Publication of KR20130103190A publication Critical patent/KR20130103190A/ko
Priority to PH12014501785A priority patent/PH12014501785B1/en
Priority to ZA2014/05918A priority patent/ZA201405918B/en
Priority to IL234133A priority patent/IL234133B/en
Priority to MX2020001697A priority patent/MX2020001697A/es
Application granted granted Critical
Publication of KR101665009B1 publication Critical patent/KR101665009B1/ko
Priority to JP2017173062A priority patent/JP2018009022A/ja
Priority to JP2019177304A priority patent/JP2019214627A/ja
Priority to JP2021178501A priority patent/JP2022025114A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020120024632A 2012-03-09 2012-03-09 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 Active KR101665009B1 (ko)

Priority Applications (31)

Application Number Priority Date Filing Date Title
KR1020120024632A KR101665009B1 (ko) 2012-03-09 2012-03-09 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
HK14112891.9A HK1199220A1 (en) 2012-03-09 2013-03-08 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
AU2013228152A AU2013228152C1 (en) 2012-03-09 2013-03-08 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
US14/383,954 US20150056223A1 (en) 2012-03-09 2013-03-08 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
JP2014560859A JP2015510880A (ja) 2012-03-09 2013-03-08 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物
TW107146976A TW201919688A (zh) 2012-03-09 2013-03-08 用於預防或治療非酒精性脂肪肝疾病之醫藥組合物
DK13757286.3T DK2838549T3 (da) 2012-03-09 2013-03-08 Farmaceutisk præparat til forebyggelse eller behandling af ikke-alkoholisk fedtleversygdom
CA2864250A CA2864250C (en) 2012-03-09 2013-03-08 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease comprising an exendin-4 conjugate
HUE13757286A HUE057245T2 (hu) 2012-03-09 2013-03-08 Gyógyászati készítmény nem-alkoholos zsírmájbetegség megelõzésére vagy kezelésére
CN201380013141.0A CN104159597A (zh) 2012-03-09 2013-03-08 用于预防或治疗非酒精性脂肪肝疾病的药学组合物
SG11201404733UA SG11201404733UA (en) 2012-03-09 2013-03-08 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
MX2014010542A MX2014010542A (es) 2012-03-09 2013-03-08 Composicion farmaceutica para la prevencion o el tratamiento de la enfermedad del higado graso no alcoholico.
TW102108194A TWI658835B (zh) 2012-03-09 2013-03-08 用於預防或治療非酒精性脂肪肝疾病之醫藥組合物
IN6694DEN2014 IN2014DN06694A (enExample) 2012-03-09 2013-03-08
CN201811396462.4A CN110075277A (zh) 2012-03-09 2013-03-08 用于预防或治疗非酒精性脂肪肝疾病的药学组合物
PL13757286T PL2838549T3 (pl) 2012-03-09 2013-03-08 Kompozycja farmaceutyczna do zapobiegania albo leczenia niealkoholowego stłuszczeniowego zapalenia wątroby
ARP130100760A AR090287A1 (es) 2012-03-09 2013-03-08 Composicion farmaceutica para la prevencion o el tratamiento de la enfermedad del higado graso no alcoholico
EP13757286.3A EP2838549B1 (en) 2012-03-09 2013-03-08 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
PCT/KR2013/001897 WO2013133667A1 (en) 2012-03-09 2013-03-08 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
NZ628828A NZ628828A (en) 2012-03-09 2013-03-08 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
PT137572863T PT2838549T (pt) 2012-03-09 2013-03-08 Composição farmacêutica para a prevenção ou tratamento da doença hepática gordurosa não alcoólica
MYPI2014002334A MY167214A (en) 2012-03-09 2013-03-08 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
ES13757286T ES2900823T3 (es) 2012-03-09 2013-03-08 Composición farmacéutica para la prevención o el tratamiento de la enfermedad del hígado graso no alcohólico
RU2014133615A RU2635966C2 (ru) 2012-03-09 2013-03-08 Фармацевтическая композиция для предупреждения или лечения неалкогольной жировой болезни печени
PH12014501785A PH12014501785B1 (en) 2012-03-09 2014-08-07 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
ZA2014/05918A ZA201405918B (en) 2012-03-09 2014-08-13 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
IL234133A IL234133B (en) 2012-03-09 2014-08-14 A medical preparation for the prevention and treatment of non-alcoholic fatty liver disease
MX2020001697A MX2020001697A (es) 2012-03-09 2014-09-03 Composicion farmaceutica para la prevencion o el tratamiento de la enfermedad del higado graso no alcoholica.
JP2017173062A JP2018009022A (ja) 2012-03-09 2017-09-08 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物
JP2019177304A JP2019214627A (ja) 2012-03-09 2019-09-27 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物
JP2021178501A JP2022025114A (ja) 2012-03-09 2021-11-01 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120024632A KR101665009B1 (ko) 2012-03-09 2012-03-09 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
KR20130103190A KR20130103190A (ko) 2013-09-23
KR101665009B1 true KR101665009B1 (ko) 2016-10-11

Family

ID=49117073

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120024632A Active KR101665009B1 (ko) 2012-03-09 2012-03-09 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물

Country Status (25)

Country Link
US (1) US20150056223A1 (enExample)
EP (1) EP2838549B1 (enExample)
JP (4) JP2015510880A (enExample)
KR (1) KR101665009B1 (enExample)
CN (2) CN110075277A (enExample)
AR (1) AR090287A1 (enExample)
AU (1) AU2013228152C1 (enExample)
CA (1) CA2864250C (enExample)
DK (1) DK2838549T3 (enExample)
ES (1) ES2900823T3 (enExample)
HK (1) HK1199220A1 (enExample)
HU (1) HUE057245T2 (enExample)
IL (1) IL234133B (enExample)
IN (1) IN2014DN06694A (enExample)
MX (2) MX2014010542A (enExample)
MY (1) MY167214A (enExample)
NZ (1) NZ628828A (enExample)
PH (1) PH12014501785B1 (enExample)
PL (1) PL2838549T3 (enExample)
PT (1) PT2838549T (enExample)
RU (1) RU2635966C2 (enExample)
SG (1) SG11201404733UA (enExample)
TW (2) TWI658835B (enExample)
WO (1) WO2013133667A1 (enExample)
ZA (1) ZA201405918B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020017916A1 (en) 2018-07-19 2020-01-23 D&D Pharmatech Inc. Pharmaceutical composition comprising polypeptide
US10746727B2 (en) 2016-12-07 2020-08-18 Korea University Research And Business Foundation Use of leucine-zipper protein for diagnosis or treatment of fatty liver
KR20200135618A (ko) 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2721062T1 (sl) 2011-06-17 2019-03-29 Hanmi Science Co., Ltd. Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
US9724420B2 (en) 2012-11-06 2017-08-08 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region
MX369656B (es) 2014-01-20 2019-11-15 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma.
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI802396B (zh) * 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
CR20180034A (es) * 2015-06-30 2018-04-16 Hanmi Pharm Ind Co Ltd Derivados de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
EP4534107A3 (en) * 2015-09-24 2025-12-10 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
EP3384935A4 (en) * 2015-12-02 2019-08-21 Hanmi Pharm. Co., Ltd. PROTEIN COMPLEX WITH FATTY ACID DERIVATIVE AND MANUFACTURING METHOD THEREFOR
AU2017332408B2 (en) 2016-09-23 2022-02-10 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
KR101964743B1 (ko) 2017-01-19 2019-08-14 울산대학교 산학협력단 Gnpat을 유효성분으로 포함하는 비알콜성 지방간염 진단용 또는 치료 예후 예측용 바이오마커 조성물
AU2018239037B2 (en) 2017-03-23 2022-05-26 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
EP3437651A1 (en) * 2017-08-03 2019-02-06 Université de Strasbourg Peptides for treatment and prevention of nonalcoholic fatty liver disease
KR102174436B1 (ko) * 2017-08-17 2020-11-04 주식회사 엘지화학 불용성 안료 화합물의 정성분석방법
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN110151980B (zh) * 2019-06-30 2022-12-09 中国药科大学 Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
KR102315866B1 (ko) * 2020-03-24 2021-10-21 한국원자력의학원 섬유화 질환 복합 치료제 개발

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100105877A1 (en) 2007-01-05 2010-04-29 Hanmi Pharmaceutical Co., Ltd. An insulinotropic complex using an immunoglobulin fragment
US20100330108A1 (en) * 2003-11-13 2010-12-30 Hanmi Pharmaceutical Co., Ltd. Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US20110200623A1 (en) 2008-07-23 2011-08-18 Hanmi Holdings Co., Ltd. Polypeptide complex comprising non-peptidyl polymer having three functional ends

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
KR101135244B1 (ko) * 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
CA2545023A1 (en) * 2003-11-25 2005-06-09 Novo Nordisk A/S Novel salicylic anilides
WO2007022518A2 (en) * 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
US20100033010A1 (en) * 2007-03-06 2010-02-11 Bridgestone Corporation Rubber track
US8249718B2 (en) * 2008-07-11 2012-08-21 Medtronic, Inc. Programming posture state-responsive therapy with nominal therapy parameters
EP2248449A1 (en) * 2009-05-08 2010-11-10 Koninklijke Philips Electronics N.V. Kitchen appliance
WO2011109787A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100330108A1 (en) * 2003-11-13 2010-12-30 Hanmi Pharmaceutical Co., Ltd. Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US20100105877A1 (en) 2007-01-05 2010-04-29 Hanmi Pharmaceutical Co., Ltd. An insulinotropic complex using an immunoglobulin fragment
US20110200623A1 (en) 2008-07-23 2011-08-18 Hanmi Holdings Co., Ltd. Polypeptide complex comprising non-peptidyl polymer having three functional ends

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10746727B2 (en) 2016-12-07 2020-08-18 Korea University Research And Business Foundation Use of leucine-zipper protein for diagnosis or treatment of fatty liver
US11442058B2 (en) 2016-12-07 2022-09-13 Korea University Research And Business Foundation Use of leucine-zipper protein for diagnosis or treatment of fatty liver
WO2020017916A1 (en) 2018-07-19 2020-01-23 D&D Pharmatech Inc. Pharmaceutical composition comprising polypeptide
US12338270B2 (en) 2018-07-19 2025-06-24 D&D Pharmatech Inc. Pharmaceutical composition comprising polypeptide
KR20200135618A (ko) 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
KR20210110252A (ko) 2019-05-23 2021-09-07 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
JP2022025114A (ja) 2022-02-09
ES2900823T3 (es) 2022-03-18
JP2019214627A (ja) 2019-12-19
AU2013228152C1 (en) 2017-11-23
KR20130103190A (ko) 2013-09-23
RU2014133615A (ru) 2016-04-27
PT2838549T (pt) 2021-12-31
HK1199220A1 (en) 2015-06-26
AR090287A1 (es) 2014-11-05
PL2838549T3 (pl) 2022-02-14
JP2018009022A (ja) 2018-01-18
CN104159597A (zh) 2014-11-19
ZA201405918B (en) 2015-08-26
EP2838549B1 (en) 2021-09-22
PH12014501785A1 (en) 2014-11-17
DK2838549T3 (da) 2022-01-03
MY167214A (en) 2018-08-14
IN2014DN06694A (enExample) 2015-05-22
PH12014501785B1 (en) 2014-11-17
NZ628828A (en) 2016-09-30
TW201919688A (zh) 2019-06-01
RU2635966C2 (ru) 2017-11-17
US20150056223A1 (en) 2015-02-26
CA2864250C (en) 2022-08-16
AU2013228152B2 (en) 2017-08-10
CN110075277A (zh) 2019-08-02
SG11201404733UA (en) 2014-09-26
MX2020001697A (es) 2020-03-20
CA2864250A1 (en) 2013-09-12
EP2838549A4 (en) 2015-12-23
TW201340981A (zh) 2013-10-16
IL234133B (en) 2020-09-30
JP2015510880A (ja) 2015-04-13
MX2014010542A (es) 2014-12-05
AU2013228152A1 (en) 2014-09-04
TWI658835B (zh) 2019-05-11
HUE057245T2 (hu) 2022-04-28
EP2838549A1 (en) 2015-02-25
WO2013133667A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
KR101665009B1 (ko) 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
KR101382593B1 (ko) 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
AU2012263098B2 (en) Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate
DK2552474T3 (en) INSULIN CONJUGATE USING AN IMMUNGLOBULIN FRAGMENT
US8476230B2 (en) Insulinotropic complex using an immunoglobulin fragment
KR102541971B1 (ko) 지속형 glp-1/글루카곤 수용체 듀얼 아고니스트의 비알콜성 지방간질환에 대한 용도
KR20140058104A (ko) 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
KR101767570B1 (ko) 항 비만 펩타이드의 지속형 결합체
HK40005973A (en) Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
EA042870B1 (ru) Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени
HK1238162A1 (en) Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190917

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10